BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37392170)

  • 21. [French ccAFU guidelines - update 2020-2022: testicular germ cell tumors].
    Murez T; Fléchon A; Savoie PH; Rocher L; Camparo P; Morel-Journel N; Ferretti L; Méjean A
    Prog Urol; 2020 Nov; 30(12S):S280-S313. PubMed ID: 33349427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poor prognosis of retroperitoneal mixed extragonadal germ cell tumors in an HIV-infected man with severe immunosuppression and bilateral cryptorchidism: a case report.
    Li R; Li H
    BMC Cancer; 2019 Mar; 19(1):244. PubMed ID: 30885154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).
    Schmoll HJ; Souchon R; Krege S; Albers P; Beyer J; Kollmannsberger C; Fossa SD; Skakkebaek NE; de Wit R; Fizazi K; Droz JP; Pizzocaro G; Daugaard G; de Mulder PH; Horwich A; Oliver T; Huddart R; Rosti G; Paz Ares L; Pont O; Hartmann JT; Aass N; Algaba F; Bamberg M; Bodrogi I; Bokemeyer C; Classen J; Clemm S; Culine S; de Wit M; Derigs HG; Dieckmann KP; Flasshove M; Garcia del Muro X; Gerl A; Germa-Lluch JR; Hartmann M; Heidenreich A; Hoeltl W; Joffe J; Jones W; Kaiser G; Klepp O; Kliesch S; Kisbenedek L; Koehrmann KU; Kuczyk M; Laguna MP; Leiva O; Loy V; Mason MD; Mead GM; Mueller RP; Nicolai N; Oosterhof GO; Pottek T; Rick O; Schmidberger H; Sedlmayer F; Siegert W; Studer U; Tjulandin S; von der Maase H; Walz P; Weinknecht S; Weissbach L; Winter E; Wittekind C;
    Ann Oncol; 2004 Sep; 15(9):1377-99. PubMed ID: 15319245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.
    Dieckmann KP; Simonsen-Richter H; Kulejewski M; Anheuser P; Zecha H; Isbarn H; Pichlmeier U
    Biomed Res Int; 2019; 2019():5030349. PubMed ID: 31275973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histologic type, staging, and distribution of germ cell tumors in Korean adults.
    Park DS; Chung MK; Chung JI; Ahn HJ; Lee ES; Choi HY; Yoon DK; Cheon J; Hong SJ; Lee YG; Yoon SM; Kim WJ; Kim HJ; Ryu SB; Ro JY
    Urol Oncol; 2008; 26(6):590-4. PubMed ID: 18367106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
    Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnosis and primary treatment of testicular tumor].
    Kliesch S
    Urologe A; 2004 Dec; 43(12):1494-9. PubMed ID: 15592706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
    Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
    Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
    Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
    JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
    Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
    Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
    J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
    Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser C; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Aurilio G; Casadei C; Tran B; Dieckmann KP; Brito M; Ruf C; Oing C; Bokemeyer C
    Eur J Cancer; 2020 Jun; 132():127-135. PubMed ID: 32361383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
    Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
    Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testicular germ cell tumors: pathogenesis, diagnosis and treatment.
    Winter C; Albers P
    Nat Rev Endocrinol; 2011 Jan; 7(1):43-53. PubMed ID: 21116298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stage-specific treatment for testicular germ cell tumours].
    Heidenreich A; Bokemeyer C; Souchon R
    Urologe A; 2009 Apr; 48(4):377-85. PubMed ID: 19252891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testicular germ cell tumors in boys <10 years: results of the protocol MAHO 98 in respect to surgery and watch & wait strategy.
    Göbel U; Haas R; Calaminus G; Botorek P; Schmidt P; Teske C; Schönberger S; Schneider DT; Harms D
    Klin Padiatr; 2013 Nov; 225(6):296-302. PubMed ID: 24158884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors.
    von Eyben FE; Blaabjerg O; Hyltoft-Petersen P; Madsen EL; Amato R; Liu F; Fritsche H
    Clin Chem Lab Med; 2001 Jan; 39(1):38-44. PubMed ID: 11256799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.